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studies), week 10 (2 studies), or week 12 (2 studies). Base- 
line HAM-D item scores were standardized and included in 
the cluster analysis, which used Ward’s minimum variance 
method to define distance. Efficacy versus placebo was 
assessed based on change from baseline in HAM-D17 total 
score, and response and remission rates. HAM-D17 total 
score at week 8/last-observation-carried-forward (LOCF) 
was analyzed using an analysis of covariance (ANCOVA) 
model with terms for study, treatment, cluster, interaction 
of treatment and cluster, and baseline HAM-D17 total score. 
Logistic regression models were used for the analysis of 
response and remission rates at week 8/LOCF with the same 
terms that were used for the ANCOVA model. 
Results: A total of 2599 patients from 9 trials had complete 
data and were included in the cluster analysis. The study 
population was 60% female and 71% white; most patients 
were moderately (59%) or markedly (31%) ill at baseline. 
Three patient clusters were identified based on baseline 
HAM-D item scores. The majority of patients (77%) fell in 
cluster 1, characterized by core symptoms and low anxiety 
(baseline HAM-D17 total score = 23). Cluster 2 (12%) had 
mild core symptoms with low anxiety (baseline HAM-D17 
total score = 20.6), and cluster 3 (11%) had core symptoms 
with high anxiety (baseline HAM-D17 total score = 27.4). For 
clusters 1 and 3, significant effects of venlafaxine versus 
placebo were observed on the change from baseline in 
HAM-D17 total score at week 8/LOCF; adjusted mean (stan- 
dard error [SE]) difference from placebo was −2.71 (0.35) 
for cluster 1 and −3.67 (0.89) for cluster 3 (both P < 0.001). 
There were no significant treatment effects on HAM-D17 
total score outcome for cluster 2 (adjusted mean (SE) 
difference, −0.77 [0.85]). Similarly, significant treatment 
effects on rates of response and remission at week 8/LOCF 
were observed for clusters 1 and 3, but not for cluster 2. 
Conclusions: Among 2599 MDD patients in 9 venlafaxine 
studies, 3 unique clusters of patients were identified based 
on HAM-D17 item scores at baseline. The clusters differed 
in their baseline core symptoms and level of anxiety, and 
may predict efficacy outcomes in patients treated with 
venlafaxine. 
Disclosure statement: Full-time employee of Pfizer Inc and 
holds Pfizer stock and stock options 
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Background: Growing evidence suggests a significant role 
of inflammation and neural plasticity processes in the 
pathogenesis of major depressive disorder (MDD) [1,2]. The 
olfactory mucosa has great potential as a tool to examine 
neurophysiological processes in psychiatric disorders, as its 
sensory neurons are replaced by neurogenesis continuously 
throughout adult life from neuronal precursor/progenitors. 
Thus, this accessible tissue closely related to the central 
nervous system, can allow the non-invasive, low-cost study 
of new biomarkers and therapeutic targets for neuropsy- 
chiatric diseases. Studies in cell cultures obtained from 
the olfactory neuroepithelium (ON) of patients with several 
different types of neuropsychiatric disorders show specific 
alterations in cellular function [3]. However, few studies are 
available using this methodology to study novel biomarkers 
of MDD. 
Objective: The aim of this study was to determine the diag- 
nostic value of inflammatory and neural plasticity markers 
(MAPK14, IL6, TNF-a, Mecp2, BDNF, GSK3, GRIA2 and FosB) 
in MDD, and to study the relationship between these 
biomarkers and course, clinical and psychometric variables. 
Methods: Twelve patients with MDD, according to DSM-IV 
criteria and seven psychiatrically healthy controls were 
included. Patients and controls were assessed with MINI 
interview for the exclusion of other mental disorders (pa- 
tients) or any mental disorder (controls). Inflammatory dis- 
eases were considered exclusion criteria. Demographical, 
course and clinical variables were recorded. Treatment- 
resistant scores were classified using the Thase and Rush 
staging method. Psychometric assessment included Hamil- 
ton Depression Rating Scale (HDRS), The State-Trait Anxiety 
Inventory (STAI), The Holmes-Rahe Social Readjustment 
Rating Scale, The Perceived Stress Scale (PSS), Global 
Assessment of Functioning (GAF) and World Health Organi- 
zation Disability Assessment Schedule (WHODAS 2.0). mRNA 
was isolated from ON cells and MAPK14, IL6, TNF-a, Mecp2, 
BDNF, GSK3, GRIA2 and Fos-B gene expression levels were 
quantified using quantitative polymerase chain reaction (q- 
PCR). Multivariate regression analyses were performed to 
test the association between mRNA levels of these biomark- 
ers and disease course, clinical and psychometric variables. 
Results: The results showed lower mRNA levels of BDNF, 
GSK3 y GRIA2 in MDD patients in comparison with controls. 
Fos-B mRNA levels were significantly higher in male patients 
in comparison with female patients, and with male con- 
trols, whereas GSK3 mRNA levels were significantly lower in 
female patients in comparison with female controls. In the 
total sample, BDNF mRNA levels were negatively correlated 
with perceived stress and state anxiety. Specific associa- 
tions in the patient group and not in the control group were 
found for GRIA2 and IL6 mRNA, which were positively cor- 
related with age, and for BDNF and IL6 mRNA levels which 
were negatively correlated with the perceived stress score. 
Conclusion: These results reveal specific BDNF, GRIA2 and 
Fos-B gene expression changes in ON cells of depressed 
patients, suggesting that (i) these biomarkers of neural 
plasticity could be relevant as diagnostic tools for MDD, 
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(ii) sex should be taken into account when studying Fos-B 
and GSK3 expression in ON cells, and (iii) the ON is a good 
cellular model to study the neurobiological mechanisms 
contributing to mental disorders. 
Disclosure statement: This abstract is partially funded by 
the Instituto de Salud Carlos III (Ministry of Economy and 
Competitiveness) (FEDER PI15/0039) 
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Background: Major depression (MDE) is a clinical syndrome 
occuring in approximately one out of six adults over a 
life-time. This syndromal transdiagnostic nosographic con- 
struct bears more than 1400 combinations of symptoms 
which may fulfil a diagnosis of MDE [1], and straddles Major 
Depressive Disorder (MDD) and Bipolar Disorder (BD). De- 
spite cross-sectional similarities, these two conditions show 
differences in their neurobiological underpinnings, clinical 
presentation, course of illness and, ultimately, functional 
outcome. Thus, prognostic and treatment implications 
warrant a differentiation between these two disorders [2]. 
Network approaches to psychopathology support that men- 
tal disorders arise from the interplay between symptoms 
in a network structure. Network analysis is a novel and 
alternative approach that outlines symptoms interactions 
in psychopathological networks and which may lead to 
significant improvements in research on and treatment of 
psychopathology [3]. Major depression has been analyzed 
using network analysis, and exposed as a complex dynamic 
system in which symptoms are directly connected to one 
another in a network structure. According to this approach, 
individuals more vulnerable to MDE have been defined as 
those with strong connections between symptoms: when 
pushed by external forces to the system (such as stress), 
they are more likely to end up in a depressed state [4]. 
The Bipolar Disorders: Improving Diagnosis, Guidance and 
Education (BRIDGE)-II-MIX study was a multicenter, multi- 
national, non-interventional, cross-sectional study aimed 
at the clinical characterization of mixed features in a large 
population of acutely depressed patients [5]. 
Aim: To characterize symptom networks in acutely de- 
pressed MDD and BD patients and to verify possible 
differences in psychopathological networks across the two 
subgroups. 
Methods: From a total of 2811 individuals with MDE from 
the BRIDGE-II-MIX study, we analyzed 7 DSM-IV-TR criteria 
for MDE and 14 researched based domain criteria for mixed 
features (RBDC) in a sample of 2758 acutely depressed 
MDD-BD patients. A total of 53 patients were excluded 
due to missing in at least one of the symptoms variables 
used as nodes for the network analysis. The global network 
was described in terms of symptom thresholds, i.e. the 
independent disposition for a symptom to be present, 
and symptom centrality. Differences in endorsement rates 
for all 24 symptoms across subgroups were assessed by 
chi-squared tests using Bonferroni corrections. Similari- 
ties in endorsement rates were examined by Spearman 
rank-order correlations. Differences in symptom network 
